An inherited cholesterol most people never test for is tied to higher stroke and heart death

Most people who get their cholesterol checked walk away with numbers for LDL, HDL, and triglycerides, and assume they have a full picture of their heart risk. There is another particle that a standard panel almost never measures, one determined largely by genetics and tied to higher rates of heart attack, stroke, and cardiovascular death. It is called lipoprotein(a), and for the roughly one in five people who carry elevated levels, the danger can go completely unnoticed.

What lipoprotein(a) actually is

Lipoprotein(a) resembles LDL cholesterol, the so-called bad cholesterol, but with a distinctive extra protein attached that changes how it behaves in the body. That structural difference is thought to make the particle more prone to lodging in artery walls and to promoting the kind of clotting and inflammation that drive cardiovascular disease. It behaves as an independent risk factor, meaning it can raise a person’s danger even when their conventional cholesterol numbers look perfectly healthy.

The particle and its clinical significance are described in detail in the reference material on the biology of lipoprotein(a), which explains how the added protein component distinguishes it from ordinary LDL. That difference is central to why the particle warrants its own attention: it is not simply more of the same cholesterol already captured on a lipid panel, but a separate contributor to arterial damage that standard testing overlooks.

Why genetics, not diet, sets the level

Unlike LDL cholesterol, which responds meaningfully to diet, exercise, and common medications, lipoprotein(a) is set overwhelmingly by inherited genes. A person’s level is largely fixed from an early age and stays relatively stable throughout life, changing little in response to the lifestyle measures that lower other cholesterol readings. Someone can eat carefully, stay active, and keep every other marker in a healthy range while still carrying a high level driven entirely by their genetic makeup.

That inherited quality has practical consequences for families. Because the trait is passed down, elevated lipoprotein(a) tends to cluster among relatives, and it can help explain cases of early heart disease that seem to run in a family without an obvious cause. A parent or sibling with a heart attack at a relatively young age can be a clue that others in the family should consider being tested.

The gap in routine testing

A conventional lipid panel is not designed to detect lipoprotein(a). Measuring it requires a separate, specific blood test that is not part of the standard order most people receive at a routine visit. As a result, a large share of the population with elevated levels has never been evaluated for it and has no idea the risk exists. The particle can be quietly elevating danger for decades while every ordinary cholesterol check comes back reassuring.

The test itself is straightforward once ordered, and because levels stay stable over a lifetime, a single measurement is generally enough to establish whether a person carries an elevated level. That makes it a one-time piece of information with lasting relevance, yet it remains outside routine screening for most people, which is a large part of why awareness stays low even among those who are diligent about monitoring their heart health.

The treatment challenge

Knowing that lipoprotein(a) is elevated presents a difficult follow-up, because the medications that reliably lower LDL cholesterol do not do much to reduce this particle. Statins, the workhorse of cholesterol treatment, have little effect on it. That gap has made the particle a focus of drug development, with therapies specifically designed to target it under investigation, though the standard toolkit for lowering cardiovascular risk does not directly address it.

In the absence of a treatment aimed squarely at the particle, the usual response is to manage every other risk factor more aggressively. A person found to have elevated lipoprotein(a) may be advised to push their LDL cholesterol lower than they otherwise would, to keep blood pressure tightly controlled, to avoid smoking, and to address diabetes or other contributors. The reasoning is that lowering the total burden of risk can partly offset the danger from a particle that cannot yet be directly lowered.

Who should consider getting checked

Testing is worth discussing for anyone with a personal or family history of early cardiovascular disease, unexplained heart problems, or a close relative already known to have elevated lipoprotein(a). Because the level is inherited and stable, a result can inform not just one person’s care but that of their siblings and children, turning a single test into information relevant to an entire family.

The broader takeaway is that a clean standard cholesterol report does not necessarily rule out an important, genetically driven source of heart risk. For the substantial minority of people carrying elevated lipoprotein(a), the particle can quietly raise the odds of a heart attack or stroke while conventional numbers stay normal. A one-time conversation with a clinician about whether the specific test is warranted is often the only way that hidden risk comes to light.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview